Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 4/20 | 0.33 |
| ▸ | KDR | P35968 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2409485 | 1.00 | XDH (0.34) | XDHSLC22A12BACE1KDRKCNH2 | |
| SCHEMBL315665 | 0.91 | MKNK1 (0.33) | MKNK1MKNK2CYP11B2 | |
| SCHEMBL3400456 | 0.91 | MKNK1 (0.33) | MKNK1MKNK2CYP11B2 | |
| SCHEMBL2412501 | 0.89 | CYP11B1 (0.39) | BACE1KDRBACE2MKNK1MKNK2 | |
| SCHEMBL2411957 | 0.89 | S1PR1 (0.35) | XDHSLC22A12BACE1KDRBACE2 | |
| SCHEMBL2411954 | 0.89 | S1PR1 (0.35) | XDHSLC22A12BACE1KDRBACE2 | |
| SCHEMBL2412498 | 0.89 | CYP11B1 (0.39) | BACE1KDRBACE2MKNK1MKNK2 | |
| SCHEMBL2413532 | 0.89 | F2R (0.35) | BACE1KDRBACE2DYRK1ACYP11B1 | |
| SCHEMBL2413534 | 0.89 | F2R (0.35) | BACE1KDRBACE2DYRK1ACYP11B1 | |
| SCHEMBL5285848 | 0.87 | CYP11B1 (0.39) | KDRMKNK1MKNK2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013010-B2 | 5-thioxylopyranose compounds | LABORATOIRES FOURNIER S.A. (FR) | 2011-09-06 | — | — | US | disclosed |
| US-20090186840-A1 | 5-Thioxylopyranose Compounds | LABORATOIRES FOURNIER S.A (FR) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186840-A1 | 5-Thioxylopyranose Compounds | TPMT, PNPO, CYP3A5 | XDH 45/4885SLC22A12 3806/4885BACE1 3683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.